Frank Torti
Frank Torti's purchase track record
Frank Torti has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/29/2022 | IMVT | $116K | +223.6% | +187.5% | +11.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.
Transaction History
| ROIV | ▼ Sell | Tax Withholding | 40,309 | $1.5M | 9/30/2026 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 40,310 | $1.4M | 6/30/2026 | View on chart |
| IMVT | ▲ Buy | Grant | 174,189 | $0 | 4/7/2026 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 160,035 | $4.4M | 3/31/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 587,390 | $2.3M | 2/23/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 587,390 | $16.2M | 2/23/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 1,012,610 | $3.9M | 2/20/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 1,012,610 | $27.5M | 2/20/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 1,400,000 | $5.4M | 2/19/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 1,400,000 | $38.4M | 2/19/2026 | View on chart |
| ROIV | ▼ Sell | Other | 64,891 | $1.5M | 12/24/2025 | View on chart |
| ROIV | ▼ Sell | Gift | 110,489 | $0 | 12/24/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 175,380 | $3.9M | 12/23/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 11,900,000 | $0 | 7/30/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 1,836,547 | $0 | 7/30/2025 | View on chart |
| IMVT | ▲ Buy | Grant | 199,365 | $0 | 4/1/2025 | View on chart |
| IMVT | ▲ Buy | Grant | 120,400 | $0 | 4/2/2024 | View on chart |
| IMVT | ▲ Buy | Grant | 121,916 | $0 | 4/12/2023 | View on chart |
| IMVT | ▲ Buy | Open Market | 20,000 | $116K | 9/29/2022 | View on chart |
| IMVT | ▲ Buy | Grant | 225,632 | $0 | 8/17/2022 | View on chart |
| IMVT | ▲ Buy | Grant | 100,126 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst
Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.